Pharmacokinetic modeling of a novel hypoxia PET tracer [(18)F]HX4 in patients with non-small cell lung cancer

新型低氧PET示踪剂[(18)F]HX4在非小细胞肺癌患者中的药代动力学建模

阅读:1

Abstract

BACKGROUND: [(18)F]HX4 is a promising new PET tracer developed to identify hypoxic areas in tumor tissue. This study analyzes [(18)F]HX4 kinetics and assesses the performance of simplified methods for quantification of [(18)F]HX4 uptake. To this end, eight patients with non-small cell lung cancer received dynamic PET scans at three different time points (0, 120, and 240 min) after injection of 426 ± 72 MBq [(18)F]HX4, each lasting 30 min. Several compartment models were fitted to time activity curves (TAC) derived from various areas within tumor tissue using image-derived input functions. RESULTS: Best fits were obtained using the reversible two-tissue compartment model with blood volume parameter (2T4k+V(B)). Simplified measures correlated well with V(T) estimates (tumor-to-blood ratio (TBr) R (2) = 0.96, tumor-to-muscle ratio R (2) = 0.94, standardized uptake value R (2) = 0.89). CONCLUSIONS: [(18)F]HX4 shows reversible kinetics in tumor tissue: 2T4k+V(B). TBr based on static imaging at 2 or 4 h can be used for quantification of [(18)F]HX4 uptake.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。